We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know
Read MoreHide Full Article
In the latest close session, Viking Therapeutics, Inc. (VKTX - Free Report) was down 2.84% at $27.73. The stock's change was less than the S&P 500's daily loss of 0.47%. At the same time, the Dow added 0.1%, and the tech-heavy Nasdaq lost 1.25%.
Shares of the company witnessed a loss of 12.72% over the previous month, trailing the performance of the Medical sector with its loss of 3.97%, and the S&P 500's gain of 1.15%.
The upcoming earnings release of Viking Therapeutics, Inc. will be of great interest to investors. On that day, Viking Therapeutics, Inc. is projected to report earnings of -$1 per share, which would represent a year-over-year decline of 23.46%.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$4.47 per share and a revenue of $0 million, signifying shifts of -40.13% and 0%, respectively, from the last year.
Investors should also pay attention to any latest changes in analyst estimates for Viking Therapeutics, Inc. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Viking Therapeutics, Inc. currently has a Zacks Rank of #2 (Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 182, this industry ranks in the bottom 27% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know
In the latest close session, Viking Therapeutics, Inc. (VKTX - Free Report) was down 2.84% at $27.73. The stock's change was less than the S&P 500's daily loss of 0.47%. At the same time, the Dow added 0.1%, and the tech-heavy Nasdaq lost 1.25%.
Shares of the company witnessed a loss of 12.72% over the previous month, trailing the performance of the Medical sector with its loss of 3.97%, and the S&P 500's gain of 1.15%.
The upcoming earnings release of Viking Therapeutics, Inc. will be of great interest to investors. On that day, Viking Therapeutics, Inc. is projected to report earnings of -$1 per share, which would represent a year-over-year decline of 23.46%.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$4.47 per share and a revenue of $0 million, signifying shifts of -40.13% and 0%, respectively, from the last year.
Investors should also pay attention to any latest changes in analyst estimates for Viking Therapeutics, Inc. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Viking Therapeutics, Inc. currently has a Zacks Rank of #2 (Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 182, this industry ranks in the bottom 27% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.